Table 2 Genotype frequencies: MTHFR C677T

All patients

254 (44.6%)

262 (46.0%)

53 (9.3%)

Status

Alive

143 (42.2%)

162 (47.8%)

34 (10%)

Dead

111 (48.3%)

100 (43.5%)

19 (8.3%)

Sex

Male

189 (43.9%)

202 (46.9%)

40 (9.3%)

Female

65 (47.1%)

60 (43.5%)

13 (9.4%)

Localization

AEG

153 (43.6%)

169 (48.1%)

29 (8.3%)

UICC 7th edtiion

Gastric cancer

99 (46.7%)

90 (42.5%)

23 (10.8%)

Localization

AEG I

63 (44.1%)

68 (47.6%)

12 (8.4%)

UICC 6th edition

AEG II/III + GC

191 (44.8%)

194 (45.5%)

41 (9.6%)

Laurén

Intestinal

137 (42.8%)

151 (47.2%)

32 (10.0%)

Non-intestinal

107 (45.7%)

107 (45.7%)

20 (8.5%)

Grading

Low grade

74 (44.6%)

75 (45.2%)

17 (10.2%)

High grade

174 (44.1%)

185 (46.8%)

36 (9.1%)

pT

pT0

14 (36.8%)

21 (55.3%)

3 (7.9%)

pT1

20 (38.5%)

28 (53.8%)

4 (7.7%)

pT2

134 (48.6%)

118 (42.8%)

24 (8.7%)

pT3

78 (42.4%)

86 (46.7%)

20 (10.9%)

pT4

8 (42.1%)

9 (47.4%)

2 (10.5%)

pN

pN0

109 (45.0%)

115 (47.5%)

18 (7.4%)

pN1

93 (46.3%)

88 (43.8%)

20 (10.0%)

pN2

31 (41.9%)

33 (44.6%)

10 (13.5%)

pN3

12 (42.9%)

15 (53.6%)

1 (3.6%)

pNx

9 (37.5%)

11 (45.8%)

4 (16.7%)

pM

pM0

236 (45.0%)

243 (46.3%)

46 (8.8%)

pM1

18 (40.9%)

19 (43.2%)

7 (15.9%)

R

R0

213 (44.7%)

218 (45.8%)

45 (9.5%)

R1/R2

41 (44.1%)

44 (47.3%)

8 (8.6%)

Neoadjuvant chemotherapy

yes

161 (43.6%)

179 (48.5%)

29 (7.9%)

no

93 (46.5%)

83 (41.5%)

24 (12.0%)

Clinical response

Responder

44 (41.9%)

52 (49.5%)

9 (8.6%)

Nonresponder

117 (44.5%)

126 (47.9%)

20 (7.6%)

TRG

1a,1b

44 (42.3%)

53 (51.0%)

7 (6.7%)

2,3

116 (44.1%)

125 (47.5%)

22 (8.4%)